首页 | 本学科首页   官方微博 | 高级检索  
     


The quality assurance process for the ARTSCAN head and neck study – A practical interactive approach for QA in 3DCRT and IMRT
Authors:Karl-Axel Johansson, Per Nilsson, Bj  rn Zackrisson, Birgitta Ohlson, Elisabeth Kjell  n, Claes Mercke, Mauricio Alvarez-Fonseca, Anette Billstr  m, Thomas Bj  rk-Eriksson, Ove Bj  r, Lars Ekberg, Signe Friesland, Magnus Karlsson, Magnus Lagerlund, Lena Lundkvist, Per-Olov L  froth, Kerstin L  fvander-Thapper, Alla Nilsson, Jan Nyman, Essie Persson, Johan Reizenstein, Hans-Olov Rosenbrand, Fredrik Wiklund,Lena Wittgren
Affiliation:

aSahlgrenska University Hospital, Göteborg, Sweden

bLund University Hospital, Lund, Sweden

cUmeå University Hospital, Umeå, Sweden

dKarolinska University Hospital at Solna, Stockholm, Sweden

eKarolinska University Hospital at Huddinge, Stockholm, Sweden

fMalmö University Hospital, Malmö, Sweden

gÖrebro University Hospital, Örebro, Sweden

hKarlstad Central Hospital, Karlstad, Sweden

Abstract:AIM: This paper describes the quality assurance (QA) work performed in the Swedish multicenter ARTSCAN (Accelerated RadioTherapy of Squamous cell CArcinomas in the head and Neck) trial to guarantee high quality in a multicenter study which involved modern radiotherapy such as 3DCRT or IMRT. MATERIALS AND METHODS: The study was closed in June 2006 with 750 randomised patients. Radiation therapy-related data for every patient were sent by each participating centre to the QA office where all trial data were reviewed, analysed and stored. In case of any deviation from the protocol, an interactive process was started between the QA office and the local responsible clinician and/or physicist to increase the compliance to the protocol for future randomised patients. Meetings and workshops were held on a regular basis for discussions on various trial-related issues and for the QA office to report on updated results. RESULTS AND DISCUSSION: This review covers the 734 patients out of a total of 750 who had entered the study. Deviations early in the study were corrected so that the overall compliance to the protocol was very high. There were only negligible variations in doses and dose distributions to target volumes for each specific site and stage. The quality of the treatments was high. Furthermore, an extensive database of treatment parameters was accumulated for future dose-volume vs. endpoint evaluations. CONCLUSIONS: This comprehensive QA programme increased the probability to draw firm conclusions from our study and may serve as a concept for QA work in future radiotherapy trials where comparatively small effects are searched for in a heterogeneous tumour population.
Keywords:Quality assurance   Multicentre trial   Head and neck   Radiotherapy   3DCRT   IMRT
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号